NASDAQ: INZY - Inozyme Pharma, Inc.

Yield per half year: +20.96%
Sector: Healthcare

Share chart Inozyme Pharma, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

Inozyme Pharma, Inc., биофармацевтическая компания, занимающаяся редкими заболеваниями, занимается разработкой терапевтических средств для лечения аномальной минерализации, влияющей на сосудистую сеть, мягкие ткани и заболевания скелета. Основным кандидатом на продукцию компании является INZ-701, растворимый рекомбинантный белок для лечения редких генетических заболеваний, связанных с дефицитом ENPP1 и ABCC6, а также для лечения кальцифилаксии. Он имеет лицензионное соглашение с Йельским университетом на определенные лечебные и профилактические продукты.

More details
Компания была зарегистрирована в 2015 году, ее штаб-квартира находится в Бостоне, штат Массачусетс.

Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

P/BV 3.05
EV/EBITDA 1.53
EBITDA -0.0207
Цена ао 5.54
Число акций ао 0.05184 млрд
Сайт http://www.inozyme.com
ISIN US45790W1080
Валюта usd
IPO date 2020-07-24
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Change price per day: +6.95% (5.18)
Change price per week: +5.52% (5.25)
Change price per month: -7.67% (6)
Change price per 3 month: -3.48% (5.74)
Change price per half year: +20.96% (4.58)
Change price per year: +66.37% (3.33)
Change price per 3 year: -42.95% (9.71)
Change price per year to date: +49.73% (3.7)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 1.64 8
P/E 0 0
EV/EBITDA -3.26 0
Total: 3.5

Efficiency

Title Value Grade
ROA, % -35.43 0
ROE, % -50.66 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.6144 10
Total: 8

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 261.41 10
Yield EPS, % 5.61 1
Total: 6.2
More

Institutions Volume Share, %
Adage Capital Partners GP L.L.C. 5537500 8.96
Pivotal bioVenture Partners Investment Advisor, LLC 4494851 7.28
Sofinnova Investments, Inc. 4280308 6.93
Rock Springs Capital Management, LP 3681174 5.96
Samlyn Capital, LLC 3372558 5.46
Eventide Asset Management LLC 3179837 5.15
Blackrock Inc. 3042330 4.93
NEA Management Company, LLC 2437689 3.95
Vanguard Group Inc 2385022 3.86
FMR, LLC 2272306 3.68

ETF Share, % Profitability for 1 year, % Dividends, %
Avantis U.S Small Cap Equity ETF 0.03012 27.774101036841 1.68271
Dimensional U.S. Core Equity 2 ETF 0.00126 30.755198832543 1.47098
Dimensional US Core Equity Market ETF 0.00045 30.983243755928 1.40618
Dimensional U.S. Equity ETF 0.00027 31.530984204131 1.3557
Goldman Sachs ActiveBeta US Small Cap Equity ETF 0.02314 31.359936575053 1.41955
ProShares Hedge Replication ETF 0.00183 5.9237999659878 1.47892
iShares Micro-Cap ETF 0.07506 34.327031588619 1.54048
iShares Russell 3000 ETF 0.00092 31.230028873917 1.43482
ProShares UltraPro Russell2000 0.0064 89.821266282945 1.47873
Vanguard Russell 3000 ETF 0 31.87314172448 1.43817
Vanguard Russell 2000 ETF 0.01 32.773459189339 1.48801



Head Job title Payment Year of birth
Mr. Axel Bolte M.B.A., M.Sc. Co-Founder, Senior Advisor & Director 1.03M 1972 (52 years)
Mr. Stefan Riley Director of Investor Relations N/A
Ms. Gayle Gironda Senior VP & Chief People Officer N/A
Dr. David Thompson M.A., M.S., Ph.D. Senior VP, Chief Scientific Officer & Chief Development Officer N/A
Dr. Demetrios Braddock M.D., Ph.D. Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer N/A
Mr. Sanjay S. Subramanian M.B.A., M.S. Senior VP, CFO, Principal Accounting Officer & Corporate Secretary 726.3k 1977 (47 years)
Dr. Soojin Kim Ph.D. Senior VP & Chief Technical Operations Officer N/A
Dr. Douglas A. Treco Ph.D. CEO & Chairman 77k 1958 (66 years)
Dr. Matthew Winton Ph.D. Senior VP & COO N/A 1978 (46 years)
Dr. Yves Sabbagh Ph.D. Chairman of Scientific Advisory Board & Senior VP N/A

Address: United States, Boston, MA , 321 Summer Street - open in Google maps, open in Yandex maps
Website: http://www.inozyme.com